http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12253345

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't
endingPage 3546
issn 1528-0020
0006-4971
issueIdentifier 10
pageRange 3540-3546
publicationName Blood
startingPage 3540
bibliographicCitation Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540–6. doi: 10.1182/blood-2007-03-080689. PMID: 17715389.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad0ac992a41cfa0af7160cef2574fa5f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a45b52a0c998da4b7f32bbf6435dc3b7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4999ad5d0b292038fe7fabcc8700a588
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_968e26e7c7303939337e837035febfde
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1392ef4064c28f2c918a6c982ef4522
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa685d0599ebeee341aa7d3b3a724e3c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_74decd3df5ca4d1c9595f04712935d86
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_17e88fbaa59f56812b87c76f8b8f768d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad31d629f9a24da0f174bee309c58605
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eb0c680fd2567f8092b12269eaba5266
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efad14d36f7281fec21789a2bd934ace
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3878510640df3512487039b346bc7b14
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5209-5126
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd6bb96fe765fc086aaf9889ce95780f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a9b56c415ee0f973e72b149ab0c829c5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_276d5abf99c2089fb3e15388072acda2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f70edd71105147118b10d9fcd0f2902
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6d00d3aba027043e0cfebb59b17c883
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59d538c82374fbed257b6d946297e8e9
date 2007-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1182/blood-2007-03-080689
https://pubmed.ncbi.nlm.nih.gov/17715389
isPartOf https://portal.issn.org/resource/ISSN/1528-0020
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243
https://portal.issn.org/resource/ISSN/0006-4971
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
discusses http://id.nlm.nih.gov/mesh/M0016884
http://id.nlm.nih.gov/mesh/M0002327
http://id.nlm.nih.gov/mesh/M0018260
http://id.nlm.nih.gov/mesh/M0482811
http://id.nlm.nih.gov/mesh/M0024527
http://id.nlm.nih.gov/mesh/M0017888
http://id.nlm.nih.gov/mesh/M0391958
http://id.nlm.nih.gov/mesh/M0001483
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8870
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8840
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644241
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8900

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID99443226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247851103

Total number of triples: 58.